生物医药行业近年来在癌症疫苗领域也获得多项进展。Moderna和默沙东联合开发的mRNA个体化癌症疫苗mRNA-4157正在多个后期临床试验中接受评估，治疗的癌症类型包括高危黑色素瘤、非小细胞肺癌、肾细胞癌、尿路上皮癌、皮肤鳞状细胞癌。它近日被行业媒 ...

Top-line, phase 3 results for Bristol-Myers Squibb's humanized monoclonal antibody (mAb) ipilimumab showed a survival benefit in patients with advanced cancer—the first ever phase 3 trial to do so.

The drug is called ipilimumab. Before it came along there were no successful treatments for advanced melanoma and less than 3% of patients survived for five years. Now, with immunotherapy regimens ...

Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improved PFS — but not OS — in patients with RCC.

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial Supported in part ...

HCC in the Rio Grande Valley: Outcomes in a predominant Latino community. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full ...

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal ...

In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine ...